INmune Bio
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
225 NE Mizner Blvd Ste 640, Boca Raton, ...Phone Number
(858) 964-3720Website
www.inmunebio.comRevenue
-Stock Symbol
INMBIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About INmune Bio
INmuneBio,Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat cancer (INB03), Mild Alzheimer's disease, Mild Cognitive Impairment and treatment resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.Explore more
INmune Bio Org Chart
CE
Controller & Vice President, Finance
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is INmune Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if INmune Bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if INmune Bio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once INmune Bio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when INmune Bio launches new products
INmune Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at INmune Bio
Check out if INmune Bio is spiking on competitors!
Earning: See what the market has to say on INmune Bio recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to INmune Bio
Compare insights from companies similar to INmune Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
INmune Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
INmune Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about INmune Bio.
INmune Bio Tech Stack
A closer look at the technologies used by INmune Bio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
reported that Xpro demonstrated safety in early Alzheimer's disease patients, with no significant safety signals other than manageable injection site reactions. The trial provided evidence that targeting neuroinflammation may slow disease progression, with a six-month trial showing benefits using EMAC as a primary cognitive endpoint in patients with high levels of neuroinflammation.
Safety, Medical Research, Pharmaceuticals, Clinical Operations
Project
INmune Bio announced results from the Mindful Trial, a Phase II study evaluating Xpro for early Alzheimer's disease. The trial showed Xpro is safe and prevented cognitive decline in patients with two or more biomarkers of inflammation, although it did not meet primary or secondary endpoints in the modified intent-to-treat population.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals, Clinical Operations, Corporate Strategy
INmune Bio News & Media
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
Management to host conference call and webcast at 4:30 pm ET on that dayINmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product OpportunitiesINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INmune Bio
Sign Up For FreeTo access detailed company insights
INmuneBio,Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TN... Read More
